NDAORALFOR SOLUTIONPriority Review
Approved
Nov 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYGEVVI is an oral small-molecule combination therapy containing doxecitine and doxribtimine approved by the FDA on November 3, 2025. The mechanism of action and specific indications have not been disclosed in available data, but the oral formulation suggests chronic disease management. The drug represents a novel dual-agent approach, though therapeutic category remains undetermined.
Growth13.9 years to LOE
Product is in launch phase with no established market spending data; commercial teams should expect 12–24 month ramp-up with staffing expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Doxecitine and Doxribtimine-Expanded Access
Thymine Kinase 2 Deficiency
Career Relevance
KYGEVVI is a newly approved oral small molecule at commercial launch, offering career opportunities in brand building, field sales expansion, and market access strategy. Working on this product means competing in an uncontested market space with long patent protection, ideal for professionals seeking launch-stage growth and differentiation potential.
Brand Manager
Worked on KYGEVVI at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.